APRICUS BIOSCIENCES, INC. (45)

Browse by Contract Category

Contracts

Open Market Sale AgreementSM, dated as of May 12, 2022, by and between Seelos Therapeutics, Inc. and Jefferies LLC (Filed With SEC on May 12, 2022)
Amendment No. 5 to Asset Purchase Agreement, dated April 8, 2022, by and between Seelos Corporation and Phoenixus AG (Filed With SEC on April 11, 2022)
Amended and Restated Employment Agreement by and between Seelos Therapeutics, Inc. and Raj Mehra, Ph.D., dated as of January 10, 2022 (Filed With SEC on January 10, 2022)
License Agreement, dated as of November 24, 2021, by and between Seelos Therapeutics, Inc. and iX Biopharma Europe Limited (Filed With SEC on November 24, 2021)
Acknowledgment and Termination Agreement, dated as of June 14, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC (Filed With SEC on June 17, 2021)
Amendment No. 3 to Agreement and Plan of Merger, dated January 16, 2019, by and among Apricus Biosciences, Inc., Arch Merger Sub, Inc. and Seelos Therapeutics, Inc (Filed With SEC on January 16, 2019)
Amendment to Convertible Promissory Note, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC, dated December 10, 2021 (Filed With SEC on March 4, 2022)
Description of Securities of Seelos Therapeutics, Inc (Filed With SEC on March 4, 2022)
Form of Convertible Promissory Note due November 23, 2024 (Filed With SEC on November 24, 2021)
Common Stock Purchase Agreement, dated as of November 24, 2021, by and between Seelos Therapeutics, Inc. and iX Biopharma Europe Limited (Filed With SEC on November 24, 2021)
Security Agreement, dated as of November 23, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC (Filed With SEC on November 24, 2021)
Securities Purchase Agreement, dated as of November 23, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC (Filed With SEC on November 24, 2021)
Underwriting Agreement, dated as of May 20, 2021, by and between Seelos Therapeutics, Inc. and Guggenheim Securities, LLC (Filed With SEC on May 21, 2021)
Non-Employee Director Compensation Policy (Filed With SEC on April 30, 2021)
Amendment No. 4 to Asset Purchase Agreement, dated February 15, 2021, by and between Seelos Corporation and Phoenixus AG (Filed With SEC on February 18, 2021)
Underwriting Agreement, dated as of January 25, 2021, by and between Seelos Therapeutics, Inc. and BTIG, LLC (Filed With SEC on January 26, 2021)
Security Agreement, dated as of December 11, 2020, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC (Filed With SEC on December 17, 2020)
Securities Purchase Agreement, dated as of December 11, 2020, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC (Filed With SEC on December 17, 2020)
Form of Convertible Promissory Note due December 11, 2022 (Filed With SEC on December 17, 2020)
Form of Warrant (Filed With SEC on September 9, 2020)
Placement Agency Agreement, dated September 4, 2020 (Filed With SEC on September 9, 2020)
Securities Purchase Agreement, dated September 4, 2020 (Filed With SEC on September 9, 2020)
Description of Securities of Seelos Therapeutics, Inc (Filed With SEC on March 17, 2020)
Amendment to License Agreement, dated as of February 8, 2019, by and among Ligand Pharmaceuticals Incorporated, Neurogen Corporation, CyDex Pharmaceuticals, Inc., and Seelos... (Filed With SEC on March 17, 2020)
Underwriting Agreement, dated as of March 11, 2020, by and between Seelos Therapeutics, Inc. and The Benchmark Company, LLC, as representative of the underwriters named therein (Filed With SEC on March 12, 2020)
Underwriting Agreement, dated as of February 10, 2020, by and between Seelos Therapeutics, Inc. and The Benchmark Company, LLC, as representative of the underwriters named therein (Filed With SEC on February 11, 2020)
Form of Underwriting Agreement (Filed With SEC on January 30, 2020)
Stock Purchase Agreement, dated as of January 2, 2020, by and between Seelos Therapeutics, Inc. and Phoenixus AG (Filed With SEC on January 3, 2020)
Amended and Restated Exclusive License Agreement, dated August 29, 2019, by and between Seelos Therapeutics, Inc. and Stuart Weg, MD (Filed With SEC on November 7, 2019)
Amendment No. 2 to Asset Purchase Agreement, dated as of December 31, 2018, by and between Seelos Therapeutics, Inc. and Phoenixus AG f/k/a Vyera Pharmaceuticals AG and Turing... (Filed With SEC on November 7, 2019)
Amendment No. 3 to Asset Purchase Agreement, dated October 15, 2019, by and between Seelos Therapeutics, Inc. and Phoenixus AG (Filed With SEC on October 21, 2019)
Form of Securities Purchase Agreement, dated August 23, 2019 (Filed With SEC on August 27, 2019)
Form of Warrant (Filed With SEC on August 27, 2019)
Placement Agency Agreement, dated August 23, 2019 (Filed With SEC on August 27, 2019)
Form of Leak-Out Agreement (Filed With SEC on August 27, 2019)
Seelos Therapeutics, Inc. 2019 Inducement Plan (Filed With SEC on August 14, 2019)
Equity Distribution Agreement, dated as of June 17, 2019, by and between Seelos Therapeutics, Inc. and Piper Jaffray & Co (Filed With SEC on June 18, 2019)
Employment Agreement by and between Seelos Therapeutics, Inc. and Raj Mehra, Ph.D., dated as of March 20, 2019 (Filed With SEC on March 26, 2019)
Non-Employee Director Compensation Policy (Filed With SEC on March 26, 2019)
Form of Fourth Amendment Agreement (Filed With SEC on March 8, 2019)
Asset Purchase Agreement, dated February 15, 2019, by and between Seelos Therapeutics, Inc. and Bioblast Pharma Ltd (Filed With SEC on February 19, 2019)
Form of Series B Warrant, issued to investors on January 31, 2019 (Filed With SEC on February 6, 2019)
Form of Series A Warrant, issued to investors on January 31, 2019 (Filed With SEC on February 6, 2019)
Form of Third Amendment Agreement (Filed With SEC on January 16, 2019)
Form of Second Amendment Agreement (Filed With SEC on January 4, 2019)